**SUPPLEMENTARY MATERIAL**

**Supplement Table 1. Ciprofloxacin use for Genitourinary Indications**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre intervention N=140 | InterventionN=221 | P-value |
| Asymptomatic bacteriuria | 6 (4) | 11 (5) | 0.762 |
| Cystitis  | 4 (3) | 18 (8) | 0.041 |
| Complicated UTI | 56 (40) | 129 (58) | 0.013 |
| Uncomplicated pyelonephritis | 12 (9) | 7 (3) | 0.025 |
| Other | 0 | 4 (1) |  |
| \*Query UTI | 62 (44) | 52 (24) | <0.001 |
| Unlikely UTI | 40 (65) | 24 (46) | 0.049 |
| Likely UTI | 22 (35) | 28 (54) | 0.049 |

UTI, Urinary tract infection

\*non-specific symptoms attributed to UTI

**Supplement Table 2. Patient Outcome Measures Pre-Intervention vs During Intervention**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre intervention n = 415 | Interventionn = 664 | P-value |
| Acute length of stay, median days (IQR) | 7.6 (0.67 – 14.4) | 8.7 (4.1 – 21.3) | 0.408 |
| Readmission within 30 days, n (%) | 58 (14) | 69 (10) | 0.075 |
| In hospital death, n (%) | 37 (9) | 59 (9) | 0.987 |
| *C. difficile* infection, n (%) | 8 (2) | 16 (2) | 0.602 |
| *C. difficile* attributable mortality, n (%) | 0 (0) | 0 (0) | - |

IQR, Interquartile range

NOTE: Patient n values differ from fluoroquinolone (FQN) n values due to some patients receiving multiple FQN orders (10 in the pre-intervention group and 18 in the intervention group).